Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.32 SEK | +0.44% | -6.76% | +4.27% |
18/04 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 | |
18/04 | Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 239M 21.87M 1.82B | Sales 2025 * | 343M 31.32M 2.61B | Capitalization | 1.5B 137M 11.46B |
---|---|---|---|---|---|
Net income 2024 * | -735M -67.18M -5.6B | Net income 2025 * | -712M -65.08M -5.43B | EV / Sales 2024 * | 8.27 x |
Net Debt 2024 * | 474M 43.33M 3.61B | Net Debt 2025 * | 733M 67.04M 5.59B | EV / Sales 2025 * | 6.53 x |
P/E ratio 2024 * |
-2.37
x | P/E ratio 2025 * |
-2.81
x | Employees | 166 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.64% |
Latest transcript on Hansa Biopharma AB
1 day | +0.44% | ||
1 week | -6.76% | ||
Current month | -6.12% | ||
1 month | -5.79% | ||
3 months | -14.62% | ||
6 months | +11.88% | ||
Current year | +4.27% |
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 20/18/20 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/12 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 29/20/29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 29/18/29 | |
Peter Nicklin
CHM | Chairman | 61 | 30/22/30 |
Mats Blom
BRD | Director/Board Member | 59 | 22/19/22 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 27.32 | +0.44% | 257,784 |
25/24/25 | 27.2 | -2.44% | 200,908 |
24/24/24 | 27.88 | -0.29% | 98,780 |
23/24/23 | 27.96 | -0.64% | 98,303 |
22/24/22 | 28.14 | -3.96% | 163,345 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 08:59 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.27% | 137M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- HNSA Stock